FermaVir receives FDA response on FV-100 for shingles, will be able to start clinical work

New York, June 5 - FermaVir Pharmaceuticals, Inc. said it received a response to its pre-Investigational New Drug application for FV-100 from the Food and Drug Administration.

The reply will allow FermaVir to proceed with clinical development of FV-100 for the treatment of shingles.

FV-100 is a pro-drug of CF-1743 and increases bioavailability of CF-1743, eight- to 10-fold in an animal model compared to dosing with CF-1743 itself. As a result, development of FV-100 as opposed to CF-1743 may have significant benefits in both amount of drug necessary for both therapeutic dosing and manufacturing.

Referring to the FDA response, Geoffrey Henson, chief executive officer of FermaVir, said in a news release: "The guidelines provided will enable us to launch a fast development track for this compound, which we believe has the potential to become a critically needed new antiviral therapy for the treatment of shingles."

FermaVir is a New York-based biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.